Abstract
BACKGROUND: Microsporum canis (Bodin, 1902) is a dermatophyte, which is widely represented in the developing and the developed world alike. Commonly transmitted from domestic animals it is particularly dangerous for immunosuppressed patients due to AIDS, cancer or transplant surgery. Search for new perspective antimycotic derivatives becomes an urgent task in the disease containment. Previously, several quinolinium analogs were screened for their antibacterial activity (E. coli, St. aurous) by our research team. Furthermore, some N-phenylbenzoquinaldinium derivatives have shown antifungal activity against Candida albicans and Candida krusei. AIMS: In this study, we sought to investigate fungicidal properties of N-arylbenzoquinaldinium derivatives against a clinical strain of Microsporum canis for future medicinal applications. MATERIALS AND METHODS: N-phenyl-[f]-benzoquinaldinium salts were prepared by a variation of the previously described technique and tested against a clinical strain of the fungus of Microsporum canis 114 harvested from pathogenic material of a patient (Perm, Russia, 2014). RESULTS: N-phenyl-[f]-benzoquinaldinium tetrafluoroborate has shown antifungal activity par to (or exceeding) that of commercially available medication. Moreover, this benzoquinaldinium analog can be potentially labelled with tritium by our nuclear-chemical method, making it amenable for the sensitive pharmacokinetic studies. CONCLUSIONS: N-phenyl-[f]-benzoquinaldinium tetrafluoroborate has been shown as a promising compound for the further development of potent antifungal agents as well as radiotracers for further elucidation of biological pathways of antifungal activity.